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Abstract
There are only sparse data on the short-term and medium-term clinical impacts of Campylobacter concisus infection. A clinical study was
performed during a 2-year period to determine the clinical manifestations in C. concisus-positive adult patients. A case patient was
deﬁned as an adult patient (‡18 years) with a C. concisus-positive stool sample during the study period. Clinical data were obtained with
use of a questionnaire supplemented with the patients’ medical records, if any. The short-term and medium-term clinical manifestations
in these patients were compared with those of patients with Campylobacter jejuni/Campylobacter coli infection. One hundred and seventy-
four C. concisus patients and 196 C. jejuni/C. coli patients participated in the study. Patients with pre-existing inﬂammatory bowel disease
or microscopic colitis or enteric co-infection were excluded from review of the clinical manifestations. Comparison of the short-term
clinical manifestations in 139 C. concisus patients with those in 187 C. jejuni/C. coli patients showed a signiﬁcantly lower prevalence of
fever, chills, mucus and blood in stools, and weight loss. However, 80% of C. concisus patients, but only 32% of C. jejuni/C. coli patients,
had diarrhoea for >2 weeks. After a 6-month follow-up period, 12% of C. concisus patients were diagnosed with microscopic colitis,
whereas no C. jejuni/C. coli patients were diagnosed with non-infective colitis. Irritable bowel symptoms were common in both groups at
follow-up. C. concisus infection seems to cause a milder course of acute gastroenteritis than C. jejuni/C. coli infection, but is associated
with more prolonged diarrhoea.
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Introduction
Campylobacter jejuni is the most commonly reported infec-
tious agent in gastrointestinal disease in the EU (http://ecdc.
europa.eu). A related species, Campylobacter concisus, was
ﬁrst isolated from human periodontal lesions in 1981, but it
is commonly isolated from saliva in healthy individuals [1,2].
Earlier studies have cultured C. concisus in diarrhoeic
stools samples from children and immunocompromised
adult patients [3–5]. However, the bacterium has also been
reported in stools from healthy children [6]. Therefore, the
precise role of C. concisus as a primary intestinal pathogen
has yet to be established, and the overall clinical impor-
tance of C. concisus infection remains unclear. Recently, an
association between C. concisus and inﬂammatory bowel dis-
ease (IBD) has been found [7–10]. In vitro, C. concisus has
shown the capability for epithelial invasion as well to cause
apoptotic leaks, and these ﬁndings support the hypothesis
that C. concisus is an intestinal pathogen [11–14]. However,
C. concisus is a very heterogeneous species that may vary
in pathogenic potential. Patients with IBD are colonized
with speciﬁc C. concisus strains in intestinal tissues, result-
ing from endogenous colonization of the patients’ oral
C. concisus [15].
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A recent study from Denmark reported a high incidence
of C. concisus, almost equal to that of C. jejuni/Campylobacter
coli, in diarrhoeic stool samples from patients in an unse-
lected population-based community [16]. Here, we present
the ﬁrst report of the short-term and medium-term clinical
outcomes in C. concisus-positive adult patients, and compare
the clinical outcomes with those of a cohort of C. jejuni/
C. coli-positive adult patients.
Materials and Methods
The study was conducted prospectively, in North Denmark
Region, located in northern Jutland, with a population of
580 515 inhabitants, from January 2009 to December 2010,
with a 6-month follow-up. Diarrhoeic stool samples were
cultured at the Department of Clinical Microbiology, Aalborg
Hospital, Aarhus University Hospital, with the ﬁlter method
as well as routine diagnosis. Identiﬁcation of Campylobacter
species was performed as described elsewhere [11,16]. C. je-
juni and C. coli were not speciated, although most infections
(>90%) were probably caused by C. jejuni [17].
A case patient was deﬁned as an adult patient (‡18 years)
with a C. concisus-positive stool sample. Comparison patients
were patients infected with C. jejuni/C. coli. The study was
unmatched. Whenever a faecal sample culture that was posi-
tive for either C. concisus or C. jejuni/C. coli, the patient was
invited by telephone by the clinical investigator to participate
in a questionnaire study. Patients were excluded if they could
not be contacted by telephone, declined to participate, were
unable to participate, resided outside North Denmark
Region, or had a terminal illness. All patients signed a written
informed consent form.
Two questionnaires (non-validated) were mailed to the
patients on the same day as the telephone interview. The
ﬁrst concerned baseline characteristics such as marital status,
smoking, drinking habits, medication, and chronic diseases.
For all patients, medical records were used simultaneously
to record their International Classiﬁcation of Diseases
(ICD)-10 diagnoses. This was used for calculation of the
Charlson comorbidity index for each patient [18]. Biochemi-
cal data from each patient were included if they had the
same index date as the positive faecal sample, or an index
date of up to 2 days before. To assess the short-term clinical
outcome, the following symptoms were used: fever (‡38C),
chills, nausea, vomiting, headache, dizziness, abdominal pain,
muscle aches, the peak number of stools passed during a 24-
h period, appearance of stools (watery, mucous, or bloody),
weight loss, prescriptions of antibiotics, and duration (in
days) of diarrhoeal disease. Duration was categorized as
£7 days, 8–14 days, and >14 days. Patients with co-patho-
gens in their faecal sample or diagnosed with IBD (ICD-10:
K50.X or K51.X) or other non-infective colitis (ICD-10:
K52.X) at baseline were excluded from analysis of the clinical
outcomes.
The second questionnaire had to be completed and
returned within 6 months from the date of the positive stool
sample. Participants were asked to report persisting or
emerging symptoms (e.g. abdominal problems and joint
pains), use of new medications, and additional visits to the
general practitioner or hospitalization within the 6 months.
Diagnoses of hospitalized patients were recorded by use of
the medical records. Additionally, patients were asked about
abdominal symptoms within the last week.
Questionnaires were analysed with Stata software, ver-
sion 10 (Stata, College Station, TX, USA). Relative preva-
lence proportions (RPPs) with corresponding 95% CIs were
calculated to estimate differences in baseline variables.
Because of the small sample size and a frequent outcome for
dichotomous variables, a modiﬁed Poisson regression analysis
was used to estimate relative risks for clinical outcome vari-
ables [19]. Estimates were adjusted for possible confounders:
age, gender, and comorbidity. Scientiﬁc and ethics approval
for the study was obtained from the Ethics Committee for
North Denmark Region (N-20080056).
Results
A total of 8939 faecal samples from 6432 adult patients were
cultured, and 315 C. concisus patients (median 60 years; inter-
quartile range (IQR) 40–72 years) and 380 C. jejuni/C. coli
patients (median 40 years; IQR 27–54 years) were identiﬁed.
Two hundred and thirteen (68%) C. concisus patients and 256
(67%) C. jejuni/C. coli patients accepted the invitation to par-
ticipate in the survey (Fig. 1). However, only 174 of 315
(55%) C. concisus patients and 196 of 380 (52%) C. jejuni/
C. coli patients actually returned the ﬁrst questionnaire. Base-
line characteristics are presented in Table 1. Forty-nine
C. concisus patients (median 65 years; range 31–90 years) had
comorbidities, as compared with only 23 C. jejuni/C. coli
patients (median 63 years; range 45–79 years) (RPP 2.4;
95% CI 1.5–3.8). Seven patients in each group had ulcerative
colitis (UC), ﬁve C. concisus patients had Crohn’s disease
(CD) and two C. concisus patients had microscopic colitis
(MC) (collagenous colitis) (ICD-10: K52.8D1) at the time of
sampling. There were no C. jejuni/C. coli patients with CD or
MC. The use of intestinal anti-inﬂammatory agents, glucocor-
ticoids and antineoplastic agents did not differ between the
two groups. However, the use of proton pump inhibitors
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was higher in the C. concisus group (18.4%) than in C. jejuni/
C. coli group (10.2%) (RPP 1.8; 95% CI 1.1–3). There was
also a clear difference in the number of co-pathogens; four
C. jejuni/C. coli patients had a co-pathogen in their stool sam-
ples (Clostridium difﬁcile, C. concisus, and Salmonella enterica,
n = 2), in contrast to 22 C. concisus patients (Clostridium difﬁ-
cile, n = 11, or S. enterica, n = 11).
The acute clinical characteristics are presented in Table 2.
A high proportion of C. jejuni/C. coli patients (69.7%)
reported fever (‡38C) and chills during their acute illness,
whereas only 23.9% of C. concisus patients reported fever
(p <0.001). More than three-quarters of all patients (81.6%
for C. concisus and 79.0% for C. jejuni/C. coli) reported abdom-
inal pain. The maximum number of stools in a 24-h period
was, on average, 11.7 for C. jejuni/C. coli patients and 9.2 for
C. concisus patients (p <0.001). Both groups reported a high
frequency of watery diarrhoea, whereas C. jejuni/C. coli
patients had a signiﬁcantly higher frequency of mucus and
macroscopic blood in their stools (p <0.05). Many C. concisus
patients (71.6%) had weight loss (mean 4.4 kg; ran-
ge 1–13 kg) during their gastroenteritis, but the number of
patients with weight loss was signiﬁcantly higher (87.1%) in
the C. jejuni/C. coli group (mean 4.4 kg; range 1–13 kg)
(p <0.01). On assessment of duration of diarrhoea, 92% of
C. jejuni/C. coli patients reported an end date with a median
duration of 10 days (IQR 7–15 days). Half of the C. concisus
FIG. 1. Flow diagram of Campylobacter
concisus and Campylobacter jejuni/Cam-
pylobacter coli patients participating in
the study from January 2009 to Decem-
ber 2010. aNo telephone number avail-
able or attempt at contact unsuccessful.
bDementia, stroke, and cancer. cOne
inﬂammatory bowel disease (IBD)
patient with C. concicus infection and
two IBD patients with C. jejuni/C. coli
infection had a co-infection. CC = Col-
lagenous Colitis (ICD-10: K52.8DI).
TABLE 1. Baseline characteristics of adult patients with






(n = 196) p-valuea
Age (years)
Mean 55.7 43.8 <0.001
Median (IQR) 59 (41–70) 42 (31–58)
Male sex 37.9 51.5 <0.001
Marital status




Unknown 1.2 3.6 0.18
Current smokers 18.4 21.9 0.44
Alcohol (average intake per week)
Low (0–4 unitsb) 79.9 70.4 <0.05
Medium (5–14 units) 16.1 18.9 0.50
High (>14 units) 4.0 5.7 0.63
Charlson comorbidity indexc
Low (0) 71.8 88.3 <0.001
Medium (1–2) 24.7 10.2 <0.001
High (>2) 3.5 1.5 0.32
Inﬂammatory bowel diseased 6.9 3.6 0.16
Daily medicatione 66.6 49 <0.001
Use of PPIsf 18.4 10.2 <0.05
Data are percentage of patients, unless otherwise indicated.
aFisher’s exact test was used for dichotomous variables, and Student’s t-test was
used for continuous variables that followed a standard normal distribution under
the null hypothesis.
bA Danish alcohol unit is 12 g (0.42 ounces).
cThree levels of comorbidity were deﬁned: 0 (low), corresponding to patients
with no recorded underlying diseases implemented in the Charlson index; 1–2
(medium); and >2 (high).
dIncluding Crohn’s disease (ICD-10: K50.X) and ulcerative colitis (ICD-10:
K51.X).
eOnly drugs with an ATC code were included.
fProton pump inhibitors (ATC code: A02BC).
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patients had diarrhoea at the time of answering the question-
naire, and the other half of the C. concisus patients (n = 66)
with ﬁxed start and end dates had a median duration of diar-
rhoea of 16 days (IQR 11–29 days). Thirty-eight C. jejuni/
C. coli patients (median 40 years; range 18–79 years) and 31
C. concisus patients (median 69 years; range 18–90 years)
were hospitalized because of their acute gastroenteritis. The
average numbers of days of hospitalization were 4 and 8 for
C. jejuni/C. coli and C. concisus patients, respectively
(p <0.001).
Blood parameters were obtained from 60 C. concisus
patients and 55 C. jejuni/C. coli patients (Table 3). Only one-
third of C. jejuni/C. coli patients (n = 19) and one-quarter of
C. concisus patients (n = 14) had leukocytosis. Half of the
C. concisus patients (52%) had normal C-reactive protein
(CRP) levels (<10 mg/L), whereas most (94%) of the C. jejuni/
C. coli patients had elevated CRP levels.
Antibiotic sensitivities were determined as described by
Nielsen et al. [16]. Clinicians received the antimicrobial sus-
ceptibility data for C. jejuni/C. coli, whereas the data for
C. concisus were only sent by speciﬁc request, owing to
uncertainty regarding the pathogenic potential of the bacte-
rium. Fifty-ﬁve per cent of C. jejuni/C. coli patients (n = 102)
reported being treated with antibiotics, whereas only 31% of
C. concisus patients (n = 43) had antibiotic treatment
(p <0.001). C. jejuni/C. coli patients were treated with cipro-
ﬂoxacin (50%), a macrolide antibiotic (30%), or other antibi-
otics (20%). C. concisus patients were mainly treated with
either ciproﬂoxacin (42%) or a macrolide (42%). Twelve
per cent of patients in both groups reported the use of anti-
propulsives (loperamide).
Fifteen C. jejuni/C. coli patients and 11 C. concisus patients
were lost to follow-up 6 months after their positive stool
sample (Table 4). Thirty-four per cent of C. concisus patients
and 25.3% C. jejuni/C. coli patients reported having trouble
with abdominal pain at 6 months, and more than half of all
patients reported having symptoms with loose stools during
the last week. Thirty-two C. concisus patients and 14 C. jejuni/
C. coli patients had a follow-up in an outpatient hospital set-
ting because of gastrointestinal illnesses, and almost
TABLE 2. Clinical characteristics of patients with Campylobacter concisus and Campylobacter jejuni/Campylobacter coli gastroen-










Fever 23.9 69.7 0.34 (0.25–0.47) <0.001 0.39 (0.28–0.54) <0.001
Chills 34.1 71.0 0.48 (0.37–0.62) <0.001 0.50 (0.39–0.66) <0.001
Nausea 67.4 73.6 0.92 (0.79–1.06) 0.2 0.94 (0.81–1.09) 0.4
Vomiting 40.6 35.9 1.13 (0.85–1.51) 0.4 1.19 (0.85–1.66) 0.2
Headache 50.8 61.8 0.82 (0.67–1.01) 0.06 0.92 (0.75–1.13) 0.4
Dizziness 50.8 59.9 0.85 (0.69–1.05) 0.1 0.88 (0.70–1.09) 0.2
Abdominal pain 81.6 79.0 1.03 (0.92–1.16) 0.6 1.13 (1.00–1.26) 0.05
Muscle aches 51.5 63.0 0.82 (0.67–1.00) 0.05 0.85 (0.69–1.05) 0.1
Consistency of stools
Watery 91.7 98.4 0.93 (0.88–0.98) <0.05 0.94 (0.89–0.99) <0.05
Mucus in stool 47.4 67.2 0.70 (0.57–0.87) <0.01 0.73 (0.59–0.90) <0.01
Blood in stool 9.9 24.7 0.40 (0.22–0.71) <0.01 0.45 (0.25–0.82) <0.05
Weight loss 71.6 87.1 0.82 (0.73–0.93) <0.01 0.83 (0.73–0.94) <0.01
Duration of diarrhoea (days)c
£7 6.2 30.4 0.20 (0.10–0.41) <0.001 0.22 (0.10–0.47) <0.001
8–14 13.9 37.6 0.37 (0.23–0.59) <0.001 0.43 (0.26–0.71) <0.001
>14 79.9 32 2.49 (1.98–3.14) <0.001 2.26 (1.77–2.90) <0.001
RR, relative risk.
Data are percentage of patients, unless otherwise indicated.
aA modiﬁed Poisson regression analysis was used to obtain estimates on RRs.
bAdjusted for age, sex, and comorbidity. Age was stratiﬁed into three groups (18–39 years, 40–59 years, and ‡60 years), and comorbidities were separated into two strata:
patients with no comorbidities and those with one or more comorbidities.
cNine patients in each group had an unknown duration of diarrhoea, and were excluded.
TABLE 3. Blood parameters from patientsa with Campylo-






(n = 55) p-value
Na+ (mM) 140 (121–147) 139 (129–147) 0.4
K+ (mM) 4 (1.5–5.2) 3.9 (2.9–4.8) 0.2
CRP (mg/L) <10 (<10–191) 65 (<10–336) <0.001
Leukocytes (·109/L) 7.5 (2.5–19) 8.9 (3.1–31.2) 0.1
Creatinine (lM) 76 (46–1131) 75 (53–417) 0.3
CRP, C-reactive protein.
Data are presented as medians (range).
aThirty-one C. concisus (52%) and 38 C. jejuni/C. coli (69%) patients were hospital-
ized.
bLeukocytes were measured in EDTA blood. Na+, K+, CRP and creatinine were
measured in plasma.
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one-quarter of C. concisus patients had a lower endoscopy
examination. No C. jejuni/C. coli patients were diagnosed with
non-infective colitis during follow-up. In contrast, two C. con-
cisus patients were diagnosed with CD and one with UC.
Sixteen C. concisus patients were diagnosed with MC during
follow-up. Six patients from each group, with no arthritis at
baseline, consulted their general practitioner because of
emerging arthralgia in one of the major joints (knee and
ankle). No patient was hospitalized because of reactive
arthritis (ReA) during the study period.
Discussion
Earlier reports regarding the clinical symptoms caused by
C. concisus, besides diarrhoea, were limited to children and
immunocompromised adult patients [3,20,21]. The present
report is the ﬁrst to describe the clinical characteristics of
C. concisus infection in adult patients in an unselected popula-
tion-based community. C. concisus infection was almost as
prevalent as infection with the common C. jejuni/C. coli
throughout the 2-year study period, as described previously
[16].
C. concisus patients had a higher frequency of comorbidities
than C. jejuni/C. coli patients, probably because of their higher
age. The higher frequency of comorbidities may explain the
high number of C. concisus patients who could not participate
in the study. A high number of C. jejuni/C. coli patients were
excluded because of lack of telephone contact. However, for
both groups, the overall age distributions among the included
and excluded cohorts were not different.
Our results show that C. concisus infection causes a
milder course of acute gastroenteritis than C. jejuni/C. coli
infection. However, we cannot rule out the effect of age on
symptomatology. C. concisus patients reported fewer fevers
and chills, as well as a lower frequency of mucus and blood
in their stools, than C. jejuni/C. coli patients. Furthermore, a
higher percentage of C. jejuni/C. coli patients reported weight
loss. Like C. jejuni/C. coli infection, C. concisus infection
resulted in upper gastrointestinal symptoms, such as vomit-
ing, in many patients. This emphasizes that C. concisus infec-
tion may be interpreted as gastroenteritis and not only as
simple enteritis. For nausea, headache, dizziness, abdominal
pain, and muscle aches, there were no signiﬁcant differences
between the two groups. Almost all C. jejuni/C. coli patients
(94%) from whom we obtained blood parameters had ele-
vated CRP levels in serum, whereas only half (48%) of
C. concisus patients had elevated CRP levels. The lower CRP
response seen in C. conicisus infection, together with less
frequent fever and chills, may present an escape mechanism
from the immune response, e.g. by interfering with host cell
immune signalling or by masking immunological recognition
patterns via molecular mimicry, as it is known for Helico-
bacter pylori [22]. The reservoir for C. concisus might be the
oral cavity, and proton pump inhibitors resulting in an
increase in gastric pH may lead to intestinal infection with
C. concisus.
In agreement with previous data, only a few C. jejuni/C. coli
patients had prolonged diarrhoea [17,23,24]. In contrast,
80% of C. concisus patients reported prolonged diarrhoea of
>2 weeks. In general, oral ﬂuid replacement is the corner-
stone of treatment of most cases of C. jejuni/C. coli enteritis,
but antibiotics may shorten the duration of symptoms
if administered early [17]. However, antibiotic therapy in
C. jejuni/C. coli patients cannot explain the large difference in
duration of diarrhoea between the groups. We have no evi-
dence regarding the efﬁcacy of antimicrobial treatment of a
C. concisus infection, and randomized clinical trials are needed
to investigate the role of antibiotics in C. concisus infection.
A high number of patients in both groups reported
abdominal pain and loose stools, and more than half of all
C. concisus patients reported a different consistency of stools
from day to day. These questions, among others, were asked
to assess whether the patients had post-infectious irritable
bowel syndrome (IBS) as shown for C. jejuni/C. coli patients
[25]. Although our self-reported data do not fulﬁl the
Rome III diagnostic criteria for IBS, the results show that
TABLE 4. Overall clinical outcome after 6 months follow-up
in adult patients with gastroenteritis with Campylobacter





(n = 172) p-value
Enteric symptomsa
Abdominal pain 34.4 25.3 0.1
Loose stools 54.6 52.4 0.8
Pain on defecation 11 11 1
Different consistency
of stools from day to day
63.3 46.4 <0.01
Mucus in stools 9.7 8.1 0.7
Visiting GP with GI disorder 12.5 6.3 0.1
Visiting GP because of arthralgia 4.7 3.5 0.8
Hospitalized with GI disorder 25 8.1 <0.001
Lower endoscopy 23.4 5.8 <0.001
Diagnosesb
Inﬂammatory bowel diseasec 2.3 0 0.08
Microscopic colitisd 12.5 0 <0.001
Irritable bowel syndrome 4.7 1.2 0.08
Other 5.5 6.9 0.6
GI, gastrointestinal; GP, general practitioner.
Data are percentage of patients, unless otherwise indicated.
aSelf-reported symptoms from the GI system within the last week 6 months
after the positive stool sample.
bPatients’ diagnoses in the time interval between the positive stool sample and
the 6-month follow-up.
cTwo C. concisus patients were diagnosed with Crohn’s disease, and one patient
was diagnosed with ulcerative colitis.
dFourteen patients were diagnosed with collagenous colitis, and two patients
were diagnosed with lymphocytic colitis.
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C. concisus patients have the same degree of late gastrointes-
tinal complaints as patients diagnosed with C. jejuni/C. coli.
During the study period, there were also more C. concisus
patients than C. jejuni/C. coli patients diagnosed with IBS,
although the numbers were small.
Six patients from each group visited their general practi-
tioner because of emerging arthralgia in one of the major
joints, which could be interpreted as possible ReA. However,
these percentages of patients with ReA seem low in compar-
ison with other studies [26–28]. The reason for this may be
recall bias, owing to the time difference between the occur-
rence of symptoms in ReA, which occur in the weeks follow-
ing the Campylobacter infection, and the 6-month follow-up
questionnaire.
Epidemiological studies with long observation periods have
focused on the possible association between C. jejuni/C. coli
infection and the risk of IBD [17,18]. Likewise, studies have
recently focused on the potential association between C. con-
cisus infection and IBD [7–10]; however, only two C. concisus
patients with CD and one patient with UC were diagnosed
during the 6-month study period. Clinical studies including
more C. concisus patients with a longer clinical follow-up per-
iod are urgently needed.
For MC, we found a possible association with C. concisus
infection, as >12% of the infected patients were diagnosed
with this disorder during the follow-up period. All patients
were diagnosed in hospital after a colonoscopy including
biopsies of the colonic mucosa. Patients with MC were all
treated with oral anti-inﬂammatory agents, and recovered.
An increased risk of MC following a stool sample positive
for C. concisus seems possible. However, the risk of MC fol-
lowing a negative stool sample also has to be investigated, to
evaluate the risk of detection bias, which cannot be excluded
in our study.
Our study participants were not matched by age and gen-
der, and, as for any retrospective study, there is potential
for recall bias among respondents, although this seems less
likely in our case-comparison study, as both clinical and fol-
low-up data were collected similarly from both groups with
the structured questionnaires.
In conclusion, C. concisus infection seems to cause a milder
course of acute gastroenteritis than C. jejuni/C. coli infection.
However, C. concisus infections were associated with more
prolonged diarrhoea, and C. concisus patients seemed to have
the same gastrointestinal complaints following the acute gas-
troenteritis as patients diagnosed with C. jejuni/C. coli infec-
tion. Our follow-up period of 6 months was too short to
allow any conclusions to be drawn regarding the risk of IBD,
but we found a possible association between C. concisus
infection and MC.
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